Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia.
Little is known about the physiological roles of the M5 muscarinic receptor, the last member of the muscarinic receptor family (M1-M5) to be cloned. In the brain, the M5 receptor subtype is preferentially expressed by dopaminergic neurons of the substantia nigra and the ventral tegmental area. Dopaminergic neurons located in the ventral tegmental area are known to play important roles in mediating both the rewarding effects of opiates and other drugs of abuse and the manifestations of opiate/drug withdrawal symptoms. We therefore speculated that acetylcholine-dependent activation of M5 receptors might modulate the manifestations of opiate reward and withdrawal. This hypothesis was tested in a series of behavioral, biochemical, and neurochemical studies using M5 receptor-deficient mice (M5-/- mice) as novel experimental tools. We found that the rewarding effects of morphine, as measured in the conditioned place preference paradigm, were substantially reduced in M5-/- mice. Furthermore, both the somatic and affective components of naloxone-induced morphine withdrawal symptoms were significantly attenuated in M5-/- mice. In contrast, the analgesic efficacy of morphine and the development of tolerance to the analgesic effects of morphine remained unaltered by the lack of M5 receptors. The finding that M5 receptor activity modulates both morphine reward and withdrawal processes suggests that M5 receptors may represent a novel target for the treatment of opiate addiction.
Basile
Anthony S
AS
Neuroscience Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA. anthony.basile@alkermes.com
Fedorova
Irina
I
Zapata
Agustin
A
Liu
Xiaoguang
X
Shippenberg
Toni
T
Duttaroy
Alokesh
A
Yamada
Masahisa
M
Wess
Jurgen
J
D000109:Acetylcholine / Q000494:pharmacology; D000698:Analgesia; D000818:Animals; D003213:Conditioning, Psychological; D004298:Dopamine / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology*; D016296:Mutagenesis; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D043642:Receptor, Muscarinic M5; D011976:Receptors, Muscarinic / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D012054:Reinforcement, Psychology; D013375:Substance Withdrawal Syndrome / Q000235:genetics / Q000503:physiopathology*; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology
D043642:Receptor, Muscarinic M5; D011976:Receptors, Muscarinic; D009020:Morphine; D000109:Acetylcholine; D004298:Dopamine